Evidence map›Paper›PMID 36459183›Full record

ArticleImmunogenetics2023

Bioinformatics analysis of structural protein to approach a vaccine candidate against Vibrio cholerae infection.

Elijah Kolawole Oladipo, Olawumi Elizabeth Akindiya, Glory Jesudara Oluwasanya, Gideon Mayowa Akanbi, Seun Elijah Olufemi, Daniel Adewole Adediran, Favour Oluwadara Bamigboye, Rasidat Oyindamola Aremu, Kehinde Temitope Kolapo, Jerry Ayobami Oluwasegun and 21 more

Abstract read
In one paragraph

Article in Immunogenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. PredictingIn silico pharmacology · 2024
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Elijah Kolawole OladipoGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria. koladipo@yahoo.co.uk.
Olawumi Elizabeth AkindiyaGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Glory Jesudara OluwasanyaGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Gideon Mayowa AkanbiGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Seun Elijah OlufemiGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Daniel Adewole AdediranGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Favour Oluwadara BamigboyeGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Rasidat Oyindamola AremuGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Kehinde Temitope KolapoGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Jerry Ayobami OluwasegunGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Hezekiah Oluwajoba AwobiyiGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Esther Moradeyo JimahGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Boluwatife Ayobami IrewoledeGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Elizabeth Oluwatoyin FolakanmiGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Odunola Abimbola OlubodunGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Samuel Adebowale AkintibuboGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Foluso Daniel OdunlamiGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Taiwo Ooreoluwa OjoGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Omodamola Paulina AkinroGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Oluwaseun Samuel HezikiahGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Adenike Titilayo OlayinkaGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Grace Asegunloluwa AbialaGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Akindele Felix IdowuGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
James Akinwunmi OgunniranGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Mary Omotoyinbo IkuomolaGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Hadijat Motunrayo AdegokeGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Usman Abiodun IdowuGenomics Unit, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Oluwaseyi Paul OlaniyanDepartment of Biochemistry, Faculty of Basic and Applied Sciences, Osun State University, P.M.B. 4494, Oke-BaaleOsogbo, Nigeria.
Olutoyin Omolara BamigboyeDepartment of Microbiology, Faculty of Science, Adeleke University, Osun State, P.M.B 250, Ede, Nigeria.
Sunday Babatunde AkindeDepartment of Microbiology, Faculty of Basic and Applied Sciences, Osun State University, P.M.B. 4494, Oke-BaaleOsogbo, Nigeria.
Musa Oladayo BabalolaDepartment of Biochemistry, College of Medicine, University of Lagos, Lagos, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bacteria Vibrio cholerae causes cholera, an acute diarrheal infection that can lead to dehydration and even death. Over 100,000 people die each year as a result of epidemic diseases; vaccination has emerged as a successful strategy for combating cholera. This study uses bioinformatics tools to create a multi-epitope vaccine against cholera infection using five structural polyproteins from the V. cholerae (CTB, TCPA, TCPF, OMPU, and OMPW). The antigenic retrieved protein sequence were analyzed using BCPred and IEDB bioinformatics tools to predict B cell and T cell epitopes, respectively, which were then linked with flexible linkers together with an adjuvant to boost it immunogenicity. The construct has a theoretical PI of 6.09, a molecular weight of 53.85 kDa, and an estimated half-life for mammalian reticulocytes in vitro of 4.4 h. These results demonstrate the construct's longevity. The vaccine design was docked against the human toll-like receptor (TLR) to evaluate compatibility and effectiveness; also other additional post-vaccination assessments were carried out on the designed vaccine. Through in silico cloning, its expression was determined. The results show that it has a CAI value of 0.1 and GC contents of 58.97% which established the adequate expression and downstream processing of the vaccine construct, and our research demonstrated that the multi-epitope subunit vaccine exhibits antigenic characteristics. Additionally, we carried out an in silico immunological simulation to examine the immune reaction to an injection. Our results strongly suggest that the vaccine candidate on further validation would induce immune response against the V. cholerae infection.

Indexed as

CholeraCholera VaccinesVibrio choleraeAnimalsCholera ToxinComputational BiologyEpitopesEpitopes, T-LymphocyteHumansMammalsCholera ToxinCholera VaccinesEpitopesEpitopes, T-LymphocyteCholeraImmune-informaticsMulti-epitopePeptide vaccineVibrio cholerae

Identifiers

PMID36459183
PMCPMC9716527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.